These two S&P 500 components have been solid performers in 2025 and are likely to continue heading higher in the new year as ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.

The stock's performance has been mixed relative to the market, and its peers and investors need to consider a couple of key ...

The last five years have seen Nvidia shares rise roughly 1,300% in value as the company went from strength to strength. It ...